Rectal microbicide development

Current Opinion in HIV and AIDS

Volumn 7, Issue 6, 2012, Pages 526-533

  McGowan, Ian ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

HIV prevention; microbicides; rectal

Indexed keywords

CARBOPOL 974P; CARRAGEENAN; CELLULOSE ACETATE; CELLULOSE SULFATE; CYANOVIRIN N; DAPIVIRINE; DEXTRIN; EMTRICITABINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; HYDROXYETHYLCELLULOSE; MARAVIROC; MICROBICIDE; N [4 CHLORO 3 (3 METHYL 2 BUTENYLOXY)PHENYL] 2 METHYL 3 FURANCARBOTHIOAMIDE; NONOXINOL 9; PLACEBO; POLYSTYRENE; PRO 2000; SAQUINAVIR; TENOFOVIR; VIVAGEL; ZINC ACETATE;

ANUS INTERCOURSE; CD4+ T LYMPHOCYTE; CHEMOPROPHYLAXIS; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; FLOW CYTOMETRY; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE HOMOSEXUAL; MAXIMUM PLASMA CONCENTRATION; MICROARRAY ANALYSIS; NONHUMAN; PATIENT COMPLIANCE; PHASE 1 CLINICAL TRIAL (TOPIC); PREEXPOSURE PROPHYLAXIS; PRIORITY JOURNAL; REVIEW; SINGLE DRUG DOSE; UNPROTECTED RECEPTIVE ANAL INTERCOURSE; UNSPECIFIED SIDE EFFECT;

ADENINE; ADMINISTRATION, RECTAL; ADMINISTRATION, TOPICAL; ANILIDES; ANTI-HIV AGENTS; CHEMOPREVENTION; CLINICAL TRIALS, PHASE I AS TOPIC; DRUG TOXICITY; FURANS; HIV INFECTIONS; HOMOSEXUALITY, MALE; HUMANS; MALE; ORGANOPHOSPHONATES;

EID: 84868466201     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e3283582bc2     Document Type: Review

References (57)

1. Stein ZA. HIV prevention: the need for methods women can use. Am J Public Health 1990; 80:460-462.
2. Jennings R, Clegg A. The inhibitory effect of spermicidal agents on replication of HSV-2 and HIV-1 in-vitro. J Antimicrob Chemother 1993; 32:71-82.
3. Tabet SR, Surawicz C, Horton S, et al. Safety and toxicity of nonoxynol-9 gel as a rectal microbicide. Sex Transm Infect 1999; 26:564-571.
4. Gross M, Celum CL, Tabet SR, et al. Acceptability of a bioadhesive nonoxynol-9 gel delivered by an applicator as a rectal microbicide. Sex Transm Dis 1999; 26:572-578.
5. Van Damme L, Ramjee G, Alary M, et al. Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial. Lancet 2002; 360:971-977.
6. McGowan I. Microbicides: a new frontier in HIV prevention. Biologicals 2006; 34:241-255.
7. Gross M, Buchbinder SP, Celum C, et al. Rectal microbicides for U.S. gay men. Are clinical trials needed? Are they feasible? HIVNET Vaccine Preparedness Study Protocol Team. Sex Transm Dis 1998; 25:296- 302.
8. Carballo-Dieguez A, O'Sullivan LF, Lin P, et al. Awareness and attitudes regarding microbicides and nonoxynol-9 use in a probability sample of gay men. AIDS Behav 2007; 11:271-276.
9. Carballo-Dieguez A, Stein Z, Saez H, et al. Frequent use of lubricants for anal sex among men who have sex with men: the HIV prevention potential of a microbicidal gel. Am J Public Health 2000; 90:1117-1121.
10. Carballo-Dieguez A, Bauermeister JA, Ventuneac A, et al. The use of rectal douches among HIV-uninfected and infected men who have unprotected receptive anal intercourse: implications for rectal microbicides. AIDS Behav 2008; 12:860-866.
11. Carballo-Dieguez A, Dolezal C, Bauermeister JA, et al. Preference for gel over suppository as delivery vehicle for a rectal microbicide: results of a randomised, crossover acceptability trial among men who have sex with men. Sex Transm Infect 2008; 84:483-487.
12. Carballo-Dieguez A, Exner T, Dolezal C, et al. Rectal microbicide acceptability: results of a volume escalation trial. Sex Transm Dis 2007; 34:224- 229.
13. McGowan I, Elliott J, Cortina G, et al. Characterization of baseline intestinal mucosal indices of injury and inflammation in men for use in rectal microbicide trials (HIV Prevention Trials Network-056). J Acquir Immune Defic Syndr 2007; 46:417-425.
14. Cohen MS, Shaw GM, McMichael AJ, Haynes BF. Acute HIV-1 Infection. N Engl J Med 2011; 364:1943-1954.
15. Boily MC, Baggaley RF, Wang L, et al. Heterosexual risk of HIV-1 infection per sexual act: systematic review and meta-analysis of observational studies. Lancet Infect Dis 2009; 9:118-129.
16. Anton PA, Elliott J, Poles MA, et al. Enhanced levels of functional HIV-1 coreceptors on human mucosal T cells demonstrated using intestinal biopsy tissue. AIDS 2000; 14:1761-1765.
17. Wolitski RJ, Fenton KA. Sexual health, HIV, and sexually transmitted infections among gay, bisexual, and other men who have sex with men in the United States. AIDS Behav 2011; 15 (Suppl 1):S9-S17.
18. Hart GJ, Williamson LM. Increase in HIV sexual risk behaviour in homosexual men in Scotland, 1996-2002: prevention failure? Sex Transm Infect 2005; 81:367-372.
19. Baral S, Scheibe A, Sullivan P, et al. Assessing priorities for combination HIV prevention research for men who have sex with men (MSM) in Africa. AIDS Behav 2012. [Epub ahead of print]
20. Gorbach PM, Manhart LE, Hess KL, et al. Anal intercourse among young heterosexuals in three sexually transmitted disease clinics in the United States. Sex Transm Dis 2009; 36:193-198.
21. Kalichman SC, Simbayi LC, Cain D, Jooste S. Heterosexual anal intercourse among community and clinical settings in Cape Town, South Africa. Sex Transm Infect 2009; 85:411-415.
22. Anton PA, Saunders T, Elliott J, et al. First phase 1 double-blind, placebocontrolled, randomized rectal microbicide trial using UC781 gel with a novel index of ex vivo efficacy. PLoS ONE 2011; 6:e23243.
23. Anton PA, Cranston RD, Kashuba A, et al. RMP-02/MTN- A Phase 1 Rectal Safety, Acceptability, Pharmacokinetic and Pharmacodynamic Study of Tenofovir 1% Gel Compared to Oral Tenofovir Disoproxil Fumerate. AIDS Res Hum Retroviruses 2012. [Epub ahead of print]
24. Herrera C, Cranage M, McGowan I, et al. Reverse transcriptase inhibitors as potential colorectal microbicides. Antimicrob Agents Chemother 2009; 53:1797-1807.
25. Herrera C, Cranage M, McGowan I, et al. Colorectal microbicide design: triple combinations of reverse transcriptase inhibitors are optimal against HIV-1 in tissue explants. AIDS 2011; 25:1971-1979.
26. Harman S, Herrera C, Armanasco N, et al. Preclinical evaluation of the HIV-1 fusion inhibitor L'644 as a potential candidate microbicide. Antimicrob Agents Chemother 2012; 56:2347-2356.
27. Herrera C, Shattock RJ. Potential use of protease inhibitors as vaginal and colorectal microbicides. Curr HIV Res 2012; 10:42-52. A interesting discussion on the potential use of protease inhibitors as candidate microbicides. Useful properties include low systemic absorption, a high genetic barrier to HIV-1 resistance, and potential activity against other pathogens including human papilloma virus (HPV) infection as well as HPV-associated dysplasia.
28. Stefanidou M, Herrera C, Armanasco N, Shattock RJ. Saquinavir inhibits early events associated with establishment of HIV-1 infection: potential role for protease inhibitors in prevention. Antimicrob Agents Chemother 2012; 56:4381-4390.
29. Abner SR, Guenthner PC, Guarner J, et al. A human colorectal explant culture to evaluate topical microbicides for the prevention of HIV infection. J Infect Dis 2005; 192:1545-1556.
30. Fletcher PS, Elliott J,Grivel JC, et al. Ex vivo culture of human colorectal tissue for the evaluation of candidate microbicides. AIDS 2006; 20:1237-1245.
31. DezzuttiCS, Rohan LC,Wang L, et al. Reformulated tenofovir gel for use as a dual compartment microbicide. J Antimicrob Chemother 2012; 67:2139-2142.
32. Patton DL, Sweeney YT, Paul KJ. A summary of preclinical topical microbicide rectal safety and efficacy evaluations in a pigtailed macaque model. Sex Transm Dis 2009; 36:350-356.
33. Tsai CC, Emau P, Jiang Y, et al. Cyanovirin-N gel as a topical microbicide prevents rectal transmission of SHIV89.6P in macaques. AIDS Res Hum Retroviruses 2003; 19:535-541.
34. Cranage M, Sharpe S, Herrera C, et al. Prevention of SIV rectal transmission and priming of T cell responses in macaques after local preexposure application of tenofovir gel. PLoS Med 2008; 5:e157.
35. Singer R, Derby N, Rodriguez A, et al. The nonnucleoside reverse transcriptase inhibitor MIV-150 in carrageenan gel prevents rectal transmission of simian/human immunodeficiency virus infection in macaques. J Virol 2011; 85:5504-5512.
36. Ventuneac A, Carballo-Dieguez A, McGowan I, et al. Acceptability of UC781 gel as a rectal microbicide among HIV-uninfected women and men. AIDS Behav 2010; 14:618-628.
37. McGowan I, Hoesley C, Cranston RD, et al. MTN- a phase 1 randomized, double blind, placebo controlled rectal safety and acceptability study of tenofovir 1% gel. In 19th Conference of Retroviruses and Opportunistic Infections Seattle, WA; 2012.
38. Fuchs EJ, Lee LA, Torbenson MS, et al. Hyperosmolar sexual lubricant causes epithelial damage in the distal colon: potential implication for HIV transmission. J Infect Dis 2007; 195:703-710.
39. Begay O, Jean-Pierre N, Abraham CJ, et al. Identification of personal lubricants that can cause rectal epithelial cell damage and enhance HIV type 1 replication in vitro. AIDS Res Hum Retroviruses 2011; 27:1019-1024.
40. Gorbach PM, Weiss RE, Fuchs E, et al. The slippery slope: lubricant use and rectal sexually transmitted infections: a newly identified risk. Sex Transm Dis 2012; 39:59-64.
41. Wang L, Schnaare RL, Dezzutti C, et al. Rectal microbicides: clinically relevant approach to the design of rectal specific placebo formulations. AIDS Res Ther 2011; 8:12.
42. Agashe H, Hu M, Rohan L. Formulation and delivery of microbicides. Curr HIV Res 2012; 10:88-96.
43. Lard-Whiteford SL. Recommendations for the nonclinical development of topical microbicides for prevention of HIV transmission: an update. J Acquir Immune Defic Syndr 2004; 36:541-552.
44. Mauck C, Rosenberg Z, Van Damme L. Recommendations for the clinical development of topical microbicides: an update. AIDS 2001; 15:857-868.
45. BuckheitRWJr, Buckheit KW. An algorithm for the preclinical development of anti-HIV topical microbicides. Curr HIV Res 2012; 10:97-104.
46. Richardson-Harman N, Lackman-Smith C, Fletcher PS, et al. Multisite comparison of antihuman immunodeficiency virus microbicide activity in explant assays using a novel endpoint analysis. J Clin Microbiol 2009; 47:3530-3539.
47. Veazey RS. Microbicide safety/efficacy studies in animals: macaques and small animal models. Curr Opin HIV AIDS 2008; 3:567-573.
48. Fernandez-Romero JA, AbrahamCJ, Rodriguez A, et al. Zinc acetate/carrageenan gels exhibit potent activity in vivo against high-dose herpes simplex virus 2 vaginal and rectal challenge. Antimicrob Agents Chemother 2012; 56:358-368.
49. Denton PW, Garcia JV. Humanized mouse models of HIV infection. AIDS Rev 2011; 13:135-148.
50. Denton PW, Othieno F, Martinez-Torres F, et al. One percentage tenofovir applied topically to humanized BLT mice and used according to the CAPRISA 004 experimental design demonstrates partial protection from vaginal HIV infection, validating the BLT model for evaluation of new microbicide candidates. J Virol 2011; 85:7582-7593.
51. Garcia-Lerma JG, Aung W, Cong ME, et al. Natural substrate concentrations can modulate the prophylactic efficacy of nucleotide HIV reverse transcriptase inhibitors. J Virol 2011; 85:6610-6617.
52. Schwartz JL, Ballagh SA, Kwok C, et al. Fourteen-day safety and acceptability study of the universal placebo gel. Contraception 2007; 75:136-141.
53. Louissaint NA, Nimmagadda S, Fuchs EJ, et al. Distribution of cell-free and cellassociated HIV surrogates in the colon after simulated receptive anal intercourse in men who have sex with men. J Acquir Immune Defic Syndr 2012; 59:10-17.
54. Cao YJ, Caffo BS, Fuchs EJ, et al. Quantification of the spatial distribution of rectally applied surrogates for microbicide and semen in colon with SPECT and magnetic resonance imaging. Br J Clin Pharmacol 2012. [Epub ahead of print]
55. Abdool KQ, Abdool Karim SS, Frohlich JA, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010; 329:1168-1174.
56. Javanbakht M, Murphy R, Gorbach P, et al. Preference and practices relating to lubricant use during anal intercourse: implications for rectal microbicides. Sex Health 2010; 7:193-198.
57. Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention inmen who have sex with men. N Engl J Med 2010; 363:2587-2599.